Health & Wellness
Medical Cannabis Study Finds Gains in Daily Function

Key PointsDaily-life interference improved more often than pain intensity among Minnesota medical…
View more
- Daily-life interference improved more often than pain intensity among Minnesota medical cannabis patients.
- Sustained relief was far less common than initial improvement across every measured outcome.
- Without a comparison group the study cannot isolate how much cannabis contributed to reported gains.
What counts as meaningful relief when chronic pain does not disappear? A lower pain score matters, but so does being able to prepare dinner, enjoy a conversation, or finish ordinary tasks with less interference. Evaluating medical cannabis requires room for both questions.
A 2026 study in Clinical Therapeutics examines this distinction among 6,010 patients in Minnesota’s medical cannabis program.1 Improvements in pain’s interference with enjoyment of life and general activity were more common than improvements in pain intensity. The findings offer an encouraging signal, while leaving important questions about causation, durability, and product selection unanswered.
Why Chronic Pain Research Measures More Than Intensity
Pain intensity and pain interference describe different experiences. Intensity asks how much something hurts. Interference asks how much that pain gets in the way. Two people reporting the same pain level may have very different abilities to work, socialize, or manage daily routines.
Think of pain as background noise. Its volume matters, but so does whether it prevents someone from following a conversation. This comparison does not explain how cannabis works biologically. It illustrates why a treatment assessment can miss something important if it measures only intensity.
The Minnesota researchers used the PEG scale, which asks about Pain, Enjoyment of life, and General activity over the previous week. Each component receives a score from zero to 10. For enjoyment and activity, higher scores mean greater interference from pain, rather than greater enjoyment or activity.
That distinction is essential: a lower interference score is an improvement. It does not necessarily demonstrate that someone walked farther, returned to work, or increased physical activity. Those outcomes would require additional measurements.
How Minnesota Tracked Medical Cannabis Patients
Researchers included people who first enrolled for chronic or intractable pain between March 2022 and February 2023 and continued purchasing medical cannabis for at least eight months. Participants had to complete a self-evaluation before each purchase, creating repeated symptom records alongside purchasing data.
The analysis focused on patients with moderate-to-severe baseline scores, defined as at least four out of 10 on the relevant measure. Researchers counted an improvement when a score fell by at least 30% within four months of the first purchase. They then examined whether that reduction persisted for at least four months after the initial improvement.
This approach captures a feature that tightly controlled trials often simplify: patients buy different products and may combine methods of administration. Flower, swallowed products such as gummies and capsules, vape oils, topical products, and products used in the mouth all appeared in the purchasing records.
Daily Life Improved More Often Than Pain Scores
Among patients with moderate-to-severe baseline scores for each component, 54.9% achieved the improvement threshold for interference with life enjoyment. The corresponding figure was 54.7% for general activity and 40.8% for pain intensity.
The table separates initial improvement from sustained improvement. Both percentage columns use patients with moderate-to-severe baseline scores for the relevant measure as their denominator.
| Measure | At Least 30% Improvement Within Four Months | Achieved and Maintained Improvement for At Least Four More Months |
|---|---|---|
| Pain intensity | 40.8% | 19.8% |
| Interference with life enjoyment | 54.9% | 29.5% |
| Interference with general activity | 54.7% | 29.3% |
| Combined PEG score | 48.9% | 25.3% |
These results support two observations. First, assessing daily life captures reported improvements that an intensity-only assessment can overlook. Second, an early response is different from a lasting response. About one in five patients with moderate-to-severe baseline pain achieved and maintained the specified pain reduction.
The study cannot establish why fewer patients met the sustained threshold. It also cannot tell us that everyone outside that group received no benefit. A threshold classifies responses; it does not describe every change in a person’s experience.
Why Product Popularity Does Not Establish Effectiveness
Flower was purchased by 77.9% of participants during the first four months, followed by swallowed products at 71.1% and vape products at 60.4%. These categories overlap because patients could purchase several product types.
Using a statistical grouping method, researchers identified five purchasing profiles. Some centered on high-THC flower or vapes, while another emphasized more balanced THC-to-CBD swallowed products. After adjustment for purchase transaction frequency, the profiles were not significantly associated with symptom improvement.
This does not demonstrate that all products work equally well. Buying frequency is an imperfect substitute for consumption, and buying a capsule bottle cannot be equated with buying one preroll. The study lacked the detailed dose, timing, and frequency information needed to compare actual exposure.
Related research on cannabis formulations for different chronic pain conditions highlights why product comparisons deserve careful attention. The Minnesota findings provide no basis for declaring the most popular format the most effective, or recommending higher THC exposure.
What This Observational Study Can Establish
The main limitation is the absence of a nonuser or placebo comparison group. Symptoms can change with other treatments, expectations, and natural fluctuations. Following patients over time records those changes but cannot isolate how much cannabis contributed.
Selection also matters. Requiring eight months of purchases excluded people who stopped earlier, including potentially those who experienced little relief. The authors acknowledge that this could overestimate effectiveness. A large sample improves the description of the selected group; it does not remove this bias.
The 2025 AHRQ review of cannabis treatments for chronic pain provides a useful comparison. It found small short-term pain improvements with some THC-containing products, alongside increased dizziness, nausea, or sedation. CBD alone was not associated with improved pain or function in the reviewed evidence. Long-term outcomes remained uncertain.
These findings can coexist with Minnesota’s observations. Trials ask whether a defined intervention improves outcomes relative to a comparator. Registries describe experiences under everyday conditions. Each helps answer questions the other cannot fully resolve.
Turning Patient Reports Into Better Research
A useful next step is to connect reported interference with specific activities patients value. As a hypothetical example, someone might describe pain falling only slightly while becoming able to stand long enough to cook. Recording both changes would make the result easier to interpret without assuming the underlying condition had improved.
Future studies could strengthen that picture by tracking:
- Personal activity goals alongside pain and interference scores.
- Actual cannabinoid doses, timing, and methods of use.
- Unwanted effects, other treatments, and reasons for stopping.
Sleep also deserves separate measurement. It is tempting to infer that improved enjoyment reflects better nights, but the Minnesota analysis did not establish that explanation. Research examining cannabis and insomnia addresses distinct outcomes and should not be treated as interchangeable with pain research.
Likewise, retail product comparisons answer a different question from treatment effectiveness. Readers examining labels can use the U.S. CBD oils and tinctures buying guide to compare concentration, ingredients, and THC content. A clearly labeled product is easier to evaluate, but its label does not establish that it will relieve chronic pain. These findings inform conversations with clinicians rather than individual treatment instructions.
The Next Question Is Who Benefits Sustainably
Interest in patient registries is expanding, including the recently announced Mississippi medical cannabis outcomes registry. Their greatest contribution will come from documenting unsuccessful experiences as carefully as successful ones.
Minnesota’s study gives researchers a concrete starting point: daily-life interference may reveal improvements that pain intensity alone misses. The next task is to identify which patients experience durable gains, under what treatment conditions, and with what unwanted effects. Measuring all three can turn an encouraging observation into evidence that better supports care.
References:
1 Christensen, G. M., Park, S. J., & Rak, D. (2026). Benefits of medical cannabis in patients with pain registered in the Minnesota Medical Cannabis Program. Clinical Therapeutics, 48, 815–821. https://doi.org/10.1016/j.clinthera.2026.05.024












